What's new? Log in Free sign up

Takeda Pharmaceutical (TAK) News and press releases

Company Profile

News

From Benzinga Pro

Takeda's Highest Dose Psoriasis Candidate Can Potentially Beat Bristol Myers' Approved Drug, Analyst Says

Analyst Color, Biotech, Large Cap, News, Health Care, Analyst Ratings, General

Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2023

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

B of A Securities Upgrades Takeda Pharmaceutical to Buy, Announces $20 Price Target

News, Upgrades, Price Target, Analyst Ratings

B of A Securities analyst Koichi Mamegano upgrades Takeda Pharmaceutical (NYSE:TAK) from Neutral to Buy and announces $20 price target.

Johnson & Johnson's Experimental Dengue Pill Shows Efficacy In Animal Studies

Biotech, Large Cap, News, Health Care, General

Takeda Presents Vedolizumab Data For Preventing Graft-Versus-Host Disease In Stem Cell Transplant Patients

Biotech, News, Health Care, General

Takeda Earlier Announced Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Biotech, News, Health Care, General

The Phase 3 GRAPHITE Study Met Its Primary Efficacy Endpoint of Significant and Clinically Meaningful Intestinal aGvHD-Free Survival as Compared to Placebo by Day 180 after Allo-HSCT. No New Safety Signals Were Seen

Takeda Reports 13% Fall In Nine Month Operating Profit, Keeps Annual Guidance Unchanged

Biotech, Earnings, Large Cap, News, Guidance, Health Care, General

Takeda Pharmaceutical Q3 Core EPS ¥168.00 Up From ¥119.00 YoY, Sales ¥1.10T Up From ¥901.30B YoY

Takeda Pharmaceutical (NYSE:TAK) reported quarterly earnings of ¥168.00 per share. This is a 41.18 percent increase over earnings of ¥119.00 per share from the same period last year. The company reported

Finch Therapeutics Halts Work On Its Only Clinical Stage Asset, Cuts 95% Of Workforce

Biotech, News, Penny Stocks, Health Care, General

HUTCHMED Out Licenses Fruquintinib To Takeda Outside China

Biotech, News, Health Care, Contracts, Movers, Trading Ideas, General

HUTCHMED Announced License To Takeda To Develop And Commercialize Fruquintinib Outside China; Hutchmed To Receive $400M Upfront On Deal Closing; Up To 730M In Potential Future Milestone Payments Plus Royalties On Net Sales

HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM, HKEX:13) today announces that its subsidiary, HUTCHMED Limited, has entered into an exclusive license agreement with a subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502, NYSE:TAK) to further the global development, commercialization and manufacture of fruquintinib outside of mainland China, Hong Kong and Macau, where it is market

Takeda's EXKIVITY Receives Approval From The NMPA Of China, Becoming The First And Only Therapy Available For Patients With EGFR Exon20 Insertion+ NSCLC

Biotech, News, FDA, General

– EXKIVITY is the First Category-1 Innovative Drug Approved for Takeda China Following a Phase 2 Global Pivotal Study – Approval Based on Data from the Phase 1/2 Clinical Trial Demonstrating

Arrowhead Pharmaceuticals Reports Underwhelming Data From Inherited Disease Study

Biotech, News, Health Care, Movers, Trading Ideas, General

Arrowhead And Takeda Announce Topline Results From SEQUOIA Phase 2 Study Of Fazirsiran In Patients With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease; Fobroris Regression Observed In 50% Of Patients Receiving Fazirsiran

Biotech, News, FDA, General

− Fibrosis regression observed in 50% of patients receiving fazirsiran − Median reductions of 94% of Z-AAT accumulation in the liver and mean reduction of 68% in

Takeda Announces Phase 3 Safety And Efficacy Results Of TAK-755 As Compared To Standard Of Care In Congenital Thrombotic Thrombocytopenic Purpura

Biotech, News, General

Results are From First and Only Phase 3 Trial in cTTP, an Ultra-Rare Disease with Limited Treatment Options cTTP is Caused by a Deficiency in ADAMTS13 Protease; 1 TAK-755 Is Designed to Replace Missing or Deficient

A Bullish Sign Appears On Takeda Pharmaceutical's Chart

Markets, Movers, Trading Ideas

Press releases

From Benzinga Pro

Phase 2b Clinical Trial Results for TYK2 Inhibitor Presented at American Academy of Dermatology Annual Meeting

Results from the Phase 2b clinical trial of TAK-279 (formerly NDI-034858), a novel allosteric TYK2 inhibitor developed by Nimbus Therapeutics and owned by Takeda (NYSE:TAK), in patients with moderate-to-severe plaque

Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque Psoriasis

Results for TAK-279 (Formerly NDI-034858) Show a Significantly Greater Proportion of Patients Achieved Psoriasis Area and Severity Index (PASI) 75 at Doses ≥5mg at 12 Weeks1 At the Highest Dose of TAK-279, 46% of

HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 14, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM, HKEX:13) today announces that, further to its announcement on January 23,

Hannon Armstrong Appoints Former EXIM Chairman Kimberly A. Reed and CEO Jeffrey A. Lipson to Board of Directors

Hannon Armstrong Sustainable Infrastructure Capital, Inc. ("Hannon Armstrong" or "HASI") (NYSE:HASI), a leading investor in climate solutions, today announced the appointment of Kimberly A. Reed and Jeffrey A. Lipson to

Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)

The Phase 3 GRAPHITE Study Met Its Primary Efficacy Endpoint of Significant and Clinically Meaningful Intestinal aGvHD-Free Survival as Compared to Placebo by Day 180 after Allo-HSCT (p<0.001) No New Safety

Nimbus Therapeutics Announces Closing of Takeda's Acquisition of TYK2 Subsidiary

Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a clinical-stage company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, today announced the

Takeda Completes Acquisition of Nimbus Therapeutics' TYK2 Program Subsidiary

U.S. FDA Approves Takeda's TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older

TAKHZYRO is the First and Only Prophylaxis Treatment Approved in the U.S. for Children 2 to <6 Years of Age With HAE1-4 Approval Supported by Extrapolation of Efficacy Data From the Phase 3 HELP Study With

Takeda Reinforces Long-term Growth Through Pipeline Advancement and Two Targeted Acquisitions; Delivers Another Strong Quarter in FY2022 Q3

Announced Agreement With Nimbus Therapeutics in December to Acquire a Potential Best-in-Class TYK2 Inhibitor, and with HUTCHMED in January to In-license Highly Selective, Oral Tyrosine Kinase Inhibitor Continued

HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China

— HUTCHMED to receive US$400 million upfront on deal closing and up to US$730 million in potential future milestone payments, totaling up to US$1.13 billion, plus royalties on net sales — — Marketing authorization

Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED's Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor

– With Marketing Authorization Submissions in the U.S., European Union and Japan Planned in 2023, Fruquintinib Offers a Potential New Treatment Option for Patients with Refractory Metastatic Colorectal Cancer –

Takeda Recognized as a Top Employer in Canada in 2023

TORONTO, Jan. 17, 2023 /CNW/ - The Top Employers Institute has named Takeda Canada Inc. ("Takeda") a top employer in Canada for 2023. The distinction is recognized by the Top Employers Institute that certifies

Takeda Named Global Top Employer for Sixth Consecutive Year

− Achieved Global Recognition and Top Employer Certification in 22 Countries from Top Employers Institute − Global Recognition Reinforces Commitment to People and Outstanding People Policies Takeda ((

Takeda's EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC

– EXKIVITY is the First Category-1 Innovative Drug Approved for Takeda China Following a Phase 2 Global Pivotal Study – Approval Based on Data from the Phase 1/2 Clinical Trial Demonstrating EXKIVITY's Clinical Benefit

Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

− Fibrosis regression observed in 50% of patients receiving fazirsiran − Median reductions of 94% of Z-AAT accumulation in the liver and mean reduction of 68% in histologic globule burden − Treatment emergent adverse

Takeda Announces Favorable Phase 3 Safety and Efficacy Results of TAK-755 as Compared to Standard of Care in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Results are From First and Only Phase 3 Trial in cTTP, an Ultra-Rare Disease with Limited Treatment Options cTTP is Caused by a Deficiency in ADAMTS13 Protease; 1 TAK-755 Is Designed to Replace Missing or Deficient

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.